Barlas RS, et al. - Researchers assessed the optimal regimen of antiplatelet therapy for secondary prevention in noncardioembolic ischemic stroke by prospectively collecting data from the Norfolk and Norwich University Hospital Stroke Register (NNUHSR) on 3,572 participants (mean age 74.96 ± 12.67) with ischemic stroke. One of three antiplatelet regimens (aspirin monotherapy, aspirin plus dipyridamole, and clopidogrel) were prescribed to patients upon hospital discharge. As per findings, aspirin plus dipyridamole initially (≤ 1 year) with a subsequent switch to clopidogrel may be of maximum benefit to the patients with non-cardioembolic stroke, with regard to mortality and MACE outcomes.